

Use your smartphone to tell CDC about any side effects after getting the COVID-19 vaccine. You'll also get reminders if you need a second vaccine dose.



1. text message check-ins from CDC (daily 1st week; weekly thru 6 weeks; then 3, 6, and 12 mo.)

vaccine recipient completes web survey*



Vaccine recipients

clinically

Select all that upply.

| Chills | Headache | Joint pains |

clinically

2. clinically important health impact reported

received medical care

Call center registry and obta



3. V-safe call center conducts active telephone follow-up on a clinically important event and takes a VAERS report if appropriate

4. pregnancy registry team conducts outreach to assess eligibility for registry and obtain consent for enrollment and follow-up

Call center






Summary of v-safe data as of February 16, 2021


	Pfizer- BioNTech	Moderna	Total
People receiving 1 or more doses in the United States*	28,374,410	26,738,383	55,220,364
Registrants completing at least 1 v-safe health check-in	1,776,960	2,121,022	3,897,982
Pregnancies reported to v-safe [†]	16,039	14,455	30,494


^{*} COVID Data Tracker as of Feb 16, 2021 (107,571 doses with manufacturer not identified)

[†] Self-reported during a **v-safe** health check-in

V-safe: Day 1 post-vaccination local reactions in pregnant and non-pregnant women aged 16-54 years*














^{*} Source: CDC unpublished v-safe data through January 13, 2021

V-safe: Day 1 post-vaccination local reactions in pregnant and non-pregnant women aged 16-54 years*







^{*} Source: CDC unpublished v-safe data through January 13, 2021



V-safe pregnancy registry

- V-safe participants who report pregnancy following COVID-19 vaccination are actively contacted to enroll in pregnancy registry*
- Participants are contacted once per trimester, after delivery, and when the infant is 3 months old[†]
- Outcomes of interest include miscarriage and still birth, pregnancy complications, maternal intensive care unit admission, adverse birth outcomes, neonatal death, infant hospitalizations, and birth defects

^{*} Must be registered in **v-safe** and have been pregnant at the time of COVID-19 vaccine receipt or within 30 days of vaccination; enrollment may discontinue when sufficient enrollment numbers are achieved

[†] Phone surveys are conducted along with maternal and infant medical record review



V-safe pregnancy registry enrollment as of February 19, 2021

Registry participants to date	(N = 1,949)
Enrolled	1,815
Not eligible*	103
Refused/declined ¹	31

- In the enrolled population, there have been 275 completed pregnancies, including 232 live births
 - Other outcomes include miscarriage, stillbirth, ectopic/tubal, other

^{*} Eligibility assessment determines whether vaccination was during pregnancy or within 30 days of last menstrual period

[†] Refused indicates those for whom eligibility could not be fully assessed because participant chose not to engage with pregnancy registry team; declined indicates those who were eligible to participate but chose not to enroll

V-safe pregnancy registry outcomes of interest in COVID-19 vaccinated pregnant women as of February 18, 2021*

	Background	V-safe pregnancy
Outcomes	rates*	registry overall
Pregnancy outcome		
Miscarriage (<20 weeks)	26%	15% [†]
Stillbirth (≥ 20 weeks)	0.6%	1%
Pregnancy complications		
Gestational diabetes	7-14%	10%
Preeclampsia or gestational hypertension ⁶	10-15%	15%
Eclampsia	0.27%	0%
Intrauterine growth restriction	3-7%	1%
Neonatal		
Preterm birth	10.1%	10%
Congenital anomalies [‡]	3%	4%
Small for gestational age [^]	3-7%	4%
Neonatal death	0.38%	0%

^{*} Sources listed on slide 33; † 93% of these were pregnancy losses <13 weeks of age; § Pre-eclampsia or gestational hypertension diagnosed during pregnancy and/or during delivery; † Congenital anomalies (overall) diagnosed after delivery only; ^ Birthweight below the 10th percentile for gestational age and sex using INTERGROWTH-21st Century growth standards